HRP20231614T1 - Spojevi pirolotriazina kao tam inhibitori - Google Patents
Spojevi pirolotriazina kao tam inhibitori Download PDFInfo
- Publication number
- HRP20231614T1 HRP20231614T1 HRP20231614TT HRP20231614T HRP20231614T1 HR P20231614 T1 HRP20231614 T1 HR P20231614T1 HR P20231614T T HRP20231614T T HR P20231614TT HR P20231614 T HRP20231614 T HR P20231614T HR P20231614 T1 HRP20231614 T1 HR P20231614T1
- Authority
- HR
- Croatia
- Prior art keywords
- phenyl
- amino
- carboxamide
- triazin
- pyrrolo
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003921 pyrrolotriazines Chemical class 0.000 title 1
- -1 aminosulfonylamino Chemical group 0.000 claims 40
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 33
- 125000001424 substituent group Chemical group 0.000 claims 33
- 150000001875 compounds Chemical class 0.000 claims 28
- 150000003839 salts Chemical class 0.000 claims 26
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 24
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims 23
- 229910020008 S(O) Inorganic materials 0.000 claims 22
- 125000000217 alkyl group Chemical group 0.000 claims 22
- 125000002947 alkylene group Chemical group 0.000 claims 21
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 20
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 19
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 16
- 229910052736 halogen Inorganic materials 0.000 claims 14
- 150000002367 halogens Chemical class 0.000 claims 14
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 13
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 13
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 12
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 11
- 229910052799 carbon Inorganic materials 0.000 claims 11
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims 11
- 239000000825 pharmaceutical preparation Substances 0.000 claims 11
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 9
- 101100005620 Caenorhabditis elegans cyb-3 gene Proteins 0.000 claims 8
- 125000006598 aminocarbonylamino group Chemical group 0.000 claims 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 7
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- 125000004750 (C1-C6) alkylaminosulfonyl group Chemical group 0.000 claims 6
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 5
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 5
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 5
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 5
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 5
- 239000003937 drug carrier Substances 0.000 claims 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 4
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 4
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims 4
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 4
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims 4
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 4
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 4
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 claims 4
- ZYCWFLSNKRWWQH-UHFFFAOYSA-N N-[4-[4-amino-7-(4-hydroxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-2-oxo-1-phenylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCC(CC1)O)C1=CC=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=CC=C1)=O ZYCWFLSNKRWWQH-UHFFFAOYSA-N 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 125000004949 alkyl amino carbonyl amino group Chemical group 0.000 claims 4
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 125000004438 haloalkoxy group Chemical group 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 125000003386 piperidinyl group Chemical group 0.000 claims 4
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 4
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 4
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 3
- 125000006698 (C1-C3) dialkylamino group Chemical group 0.000 claims 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 3
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 3
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 3
- 101100059439 Caenorhabditis elegans cyb-1 gene Proteins 0.000 claims 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 101100273638 Caenorhabditis elegans cya-1 gene Proteins 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- MVFGYMXGYJXEFF-UHFFFAOYSA-N N-[4-(4-amino-7-piperidin-4-ylpyrrolo[2,1-f][1,2,4]triazin-5-yl)-3-fluorophenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCNCC1)C1=C(C=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=C(C=C1)F)=O)F MVFGYMXGYJXEFF-UHFFFAOYSA-N 0.000 claims 2
- ONSJKYVPJNEILC-UHFFFAOYSA-N N-[4-[4-amino-7-(4-hydroxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]-3-fluorophenyl]-2-oxo-1-phenylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCC(CC1)O)C1=C(C=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=CC=C1)=O)F ONSJKYVPJNEILC-UHFFFAOYSA-N 0.000 claims 2
- YTGKQQWXYQLBGX-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-hydroxyethyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]-3-fluorophenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)CCO)C1=C(C=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=C(C=C1)F)=O)F YTGKQQWXYQLBGX-UHFFFAOYSA-N 0.000 claims 2
- UVHZFGWSWUQZFX-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methoxyethyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]-3-fluorophenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)CCOC)C1=C(C=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=C(C=C1)F)=O)F UVHZFGWSWUQZFX-UHFFFAOYSA-N 0.000 claims 2
- CLKZYSCOSIBANL-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(dimethylcarbamoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]-3-fluorophenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(=O)N(C)C)C1=C(C=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=C(C=C1)F)=O)F CLKZYSCOSIBANL-UHFFFAOYSA-N 0.000 claims 2
- DUXXBRYGDLQJQM-UHFFFAOYSA-N N-[4-[4-amino-7-[1-[ethyl(methyl)carbamoyl]piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]-3-fluorophenyl]-1-(4-fluorophenyl)-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(=O)N(C)CC)C1=C(C=C(C=C1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=C(C=C1)F)=O)F DUXXBRYGDLQJQM-UHFFFAOYSA-N 0.000 claims 2
- HSXPKDPRRLEBQG-UHFFFAOYSA-N N-[4-[4-amino-7-[1-[ethyl(methyl)carbamoyl]piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-1-(4-fluorophenyl)-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(=O)N(C)CC)C1=CC=C(C=C1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=C(C=C1)F)=O HSXPKDPRRLEBQG-UHFFFAOYSA-N 0.000 claims 2
- ZMODBJGIKIUPSW-UHFFFAOYSA-N N-[4-[4-amino-7-[1-[ethyl(methyl)carbamoyl]piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(=O)N(C)CC)C1=CC=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=C(C=C1)F)=O ZMODBJGIKIUPSW-UHFFFAOYSA-N 0.000 claims 2
- PLCVJNJRUVNDEY-UHFFFAOYSA-N N-[4-[7-(1-acetylpiperidin-4-yl)-4-aminopyrrolo[2,1-f][1,2,4]triazin-5-yl]-3-fluorophenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide Chemical compound C(C)(=O)N1CCC(CC1)C1=CC(=C2C(=NC=NN21)N)C1=C(C=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=C(C=C1)F)=O)F PLCVJNJRUVNDEY-UHFFFAOYSA-N 0.000 claims 2
- QRYMEHUICLZZCD-UHFFFAOYSA-N N-[4-[7-(1-acetylpiperidin-4-yl)-4-aminopyrrolo[2,1-f][1,2,4]triazin-5-yl]-3-fluorophenyl]-2-oxo-1-phenylpyridine-3-carboxamide Chemical compound C(C)(=O)N1CCC(CC1)C1=CC(=C2C(=NC=NN21)N)C1=C(C=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=CC=C1)=O)F QRYMEHUICLZZCD-UHFFFAOYSA-N 0.000 claims 2
- 108091000080 Phosphotransferase Proteins 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 102000020233 phosphotransferase Human genes 0.000 claims 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 claims 1
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 1
- 125000004760 (C1-C4) alkylsulfonylamino group Chemical group 0.000 claims 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- ZXNZHVDQMZJUKH-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide Chemical compound O=C1C(C(=O)N)=CC=CN1C1=CC=C(F)C=C1 ZXNZHVDQMZJUKH-UHFFFAOYSA-N 0.000 claims 1
- CDYZISGCDITLOI-UHFFFAOYSA-N 4-amino-5-[4-[[3-(3-fluorophenyl)-2,4-dioxo-1-propan-2-ylpyrimidine-5-carbonyl]amino]phenyl]-N,N-dimethylpyrrolo[2,1-f][1,2,4]triazine-7-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C(=O)N(C)C)C1=CC=C(C=C1)NC(=O)C=1C(N(C(N(C=1)C(C)C)=O)C1=CC(=CC=C1)F)=O CDYZISGCDITLOI-UHFFFAOYSA-N 0.000 claims 1
- NFCXQIHBUDNOQY-UHFFFAOYSA-N 5-N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-2-methyl-6-oxo-1-phenylpyridine-3,5-dicarboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C=1C(N(C(=C(C=1)C(=O)N)C)C1=CC=CC=C1)=O NFCXQIHBUDNOQY-UHFFFAOYSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims 1
- 201000003076 Angiosarcoma Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 125000003830 C1- C4 alkylcarbonylamino group Chemical group 0.000 claims 1
- 101100310926 Caenorhabditis elegans sra-3 gene Proteins 0.000 claims 1
- 101100310927 Caenorhabditis elegans sra-4 gene Proteins 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102100038417 Cytoplasmic FMR1-interacting protein 1 Human genes 0.000 claims 1
- 101710181791 Cytoplasmic FMR1-interacting protein 1 Proteins 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 108010081348 HRT1 protein Hairy Proteins 0.000 claims 1
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010024612 Lipoma Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- SDLQPJGQEFSRRE-UHFFFAOYSA-N N-[4-(4-amino-7-ethylpyrrolo[2,1-f][1,2,4]triazin-5-yl)-3-fluorophenyl]-2-oxo-1-phenylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2CC)C1=C(C=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=CC=C1)=O)F SDLQPJGQEFSRRE-UHFFFAOYSA-N 0.000 claims 1
- DLOQHHJANJFFJT-UHFFFAOYSA-N N-[4-(4-amino-7-ethylpyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl]-1-(4-fluorophenyl)-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2CC)C1=CC=C(C=C1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=C(C=C1)F)=O DLOQHHJANJFFJT-UHFFFAOYSA-N 0.000 claims 1
- WDUZHMCHWHGCJJ-DEOSSOPVSA-N N-[4-(4-amino-7-ethylpyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl]-1-[(1R)-2-hydroxy-1-phenylethyl]-2-oxopyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2CC)C1=CC=C(C=C1)NC(=O)C=1C(N(C=CC=1)[C@@H](CO)C1=CC=CC=C1)=O WDUZHMCHWHGCJJ-DEOSSOPVSA-N 0.000 claims 1
- SXNWEPPMFXZDBN-GOSISDBHSA-N N-[4-(4-amino-7-ethylpyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl]-1-[(2R)-1-hydroxybutan-2-yl]-2-oxopyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2CC)C1=CC=C(C=C1)NC(=O)C=1C(N(C=CC=1)[C@H](CC)CO)=O SXNWEPPMFXZDBN-GOSISDBHSA-N 0.000 claims 1
- ASXZIOFDDZWNBH-CQSZACIVSA-N N-[4-(4-amino-7-ethylpyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl]-1-[(2R)-1-hydroxypropan-2-yl]-2-oxopyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2CC)C1=CC=C(C=C1)NC(=O)C=1C(N(C=CC=1)[C@@H](CO)C)=O ASXZIOFDDZWNBH-CQSZACIVSA-N 0.000 claims 1
- YOGPBAXHXFDATQ-UHFFFAOYSA-N N-[4-(4-amino-7-ethylpyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl]-1-benzyl-2-oxopyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2CC)C1=CC=C(C=C1)NC(=O)C=1C(N(C=CC=1)CC1=CC=CC=C1)=O YOGPBAXHXFDATQ-UHFFFAOYSA-N 0.000 claims 1
- XLRSOQOKZYHHPE-UHFFFAOYSA-N N-[4-(4-amino-7-ethylpyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl]-1-methyl-2-oxopyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2CC)C1=CC=C(C=C1)NC(=O)C=1C(N(C=CC=1)C)=O XLRSOQOKZYHHPE-UHFFFAOYSA-N 0.000 claims 1
- SSNOOYVRHMFBIF-UHFFFAOYSA-N N-[4-(4-amino-7-methylpyrrolo[2,1-f][1,2,4]triazin-5-yl)-3-fluorophenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C)C1=C(C=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=C(C=C1)F)=O)F SSNOOYVRHMFBIF-UHFFFAOYSA-N 0.000 claims 1
- UJBDZOICZAPMEZ-UHFFFAOYSA-N N-[4-(4-amino-7-methylpyrrolo[2,1-f][1,2,4]triazin-5-yl)-3-fluorophenyl]-2-oxo-1-phenylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C)C1=C(C=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=CC=C1)=O)F UJBDZOICZAPMEZ-UHFFFAOYSA-N 0.000 claims 1
- WDSAVECIVQHDAD-UHFFFAOYSA-N N-[4-(4-amino-7-methylpyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C)C1=CC=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=C(C=C1)F)=O WDSAVECIVQHDAD-UHFFFAOYSA-N 0.000 claims 1
- GTZDUBKNXPYACI-UHFFFAOYSA-N N-[4-(4-amino-7-methylpyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl]-2-oxo-1-phenylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C)C1=CC=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=CC=C1)=O GTZDUBKNXPYACI-UHFFFAOYSA-N 0.000 claims 1
- BHGAULURFLXYMT-UHFFFAOYSA-N N-[4-(4-amino-7-piperidin-4-ylpyrrolo[2,1-f][1,2,4]triazin-5-yl)-3-fluorophenyl]-2-oxo-1-phenylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCNCC1)C1=C(C=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=CC=C1)=O)F BHGAULURFLXYMT-UHFFFAOYSA-N 0.000 claims 1
- ZPVSNCIOAMEWBR-UHFFFAOYSA-N N-[4-(4-amino-7-piperidin-4-ylpyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCNCC1)C1=CC=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=C(C=C1)F)=O ZPVSNCIOAMEWBR-UHFFFAOYSA-N 0.000 claims 1
- FFCKHBSETQPNFE-UHFFFAOYSA-N N-[4-(4-amino-7-piperidin-4-ylpyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl]-2-oxo-1-phenylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCNCC1)C1=CC=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=CC=C1)=O FFCKHBSETQPNFE-UHFFFAOYSA-N 0.000 claims 1
- NPMHPYDYYNJHLT-UHFFFAOYSA-N N-[4-[4-amino-7-(1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C)C1=CC=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=C(C=C1)F)=O NPMHPYDYYNJHLT-UHFFFAOYSA-N 0.000 claims 1
- CDLLABUAFGKJDH-UHFFFAOYSA-N N-[4-[4-amino-7-(1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-2-oxo-1-phenylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C)C1=CC=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=CC=C1)=O CDLLABUAFGKJDH-UHFFFAOYSA-N 0.000 claims 1
- MFXKIWDPRIHODU-UHFFFAOYSA-N N-[4-[4-amino-7-(1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-6-methyl-2-oxo-1-phenyl-5-pyrimidin-2-ylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C)C1=CC=C(C=C1)NC(=O)C=1C(N(C(=C(C=1)C1=NC=CC=N1)C)C1=CC=CC=C1)=O MFXKIWDPRIHODU-UHFFFAOYSA-N 0.000 claims 1
- LFZTUWMBFUXEBV-UHFFFAOYSA-N N-[4-[4-amino-7-(1-methylsulfonylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]-3-fluorophenyl]-2-oxo-1-phenylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)S(=O)(=O)C)C1=C(C=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=CC=C1)=O)F LFZTUWMBFUXEBV-UHFFFAOYSA-N 0.000 claims 1
- GTYUKUURXPBNLQ-UHFFFAOYSA-N N-[4-[4-amino-7-(1-methylsulfonylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)S(=O)(=O)C)C1=CC=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=C(C=C1)F)=O GTYUKUURXPBNLQ-UHFFFAOYSA-N 0.000 claims 1
- UKJAACLEQSSYIE-UHFFFAOYSA-N N-[4-[4-amino-7-(1-methylsulfonylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-2-oxo-1-phenylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)S(=O)(=O)C)C1=CC=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=CC=C1)=O UKJAACLEQSSYIE-UHFFFAOYSA-N 0.000 claims 1
- OXPQSGRKFNVPAM-UHFFFAOYSA-N N-[4-[4-amino-7-(4-cyanocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]-3-fluorophenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide Chemical compound Nc1ncnn2c(cc(-c3ccc(NC(=O)c4cccn(-c5ccc(F)cc5)c4=O)cc3F)c12)C1CCC(CC1)C#N OXPQSGRKFNVPAM-UHFFFAOYSA-N 0.000 claims 1
- PHPKMXFRPJBGSR-UHFFFAOYSA-N N-[4-[4-amino-7-(4-cyanocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]-3-fluorophenyl]-2-oxo-1-phenylpyridine-3-carboxamide Chemical compound Nc1ncnn2c(cc(-c3ccc(NC(=O)c4cccn(-c5ccccc5)c4=O)cc3F)c12)C1CCC(CC1)C#N PHPKMXFRPJBGSR-UHFFFAOYSA-N 0.000 claims 1
- HVMCHMJVEKCRCI-UHFFFAOYSA-N N-[4-[4-amino-7-(4-cyanocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide Chemical compound Nc1ncnn2c(cc(-c3ccc(NC(=O)c4cccn(-c5ccc(F)cc5)c4=O)cc3)c12)C1CCC(CC1)C#N HVMCHMJVEKCRCI-UHFFFAOYSA-N 0.000 claims 1
- KZRUTRKOHDQVNC-UHFFFAOYSA-N N-[4-[4-amino-7-(4-cyanocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-2-oxo-1-phenylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCC(CC1)C#N)C1=CC=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=CC=C1)=O KZRUTRKOHDQVNC-UHFFFAOYSA-N 0.000 claims 1
- NSGSTMADVSYLQK-UHFFFAOYSA-N N-[4-[4-amino-7-(4-hydroxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCC(CC1)O)C1=CC=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=C(C=C1)F)=O NSGSTMADVSYLQK-UHFFFAOYSA-N 0.000 claims 1
- LLWJULPMRBZXBX-UHFFFAOYSA-N N-[4-[4-amino-7-(oxan-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]-3-fluorophenyl]-2-oxo-1-phenylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCOCC1)C1=C(C=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=CC=C1)=O)F LLWJULPMRBZXBX-UHFFFAOYSA-N 0.000 claims 1
- WRADGJQBDXJRIT-UHFFFAOYSA-N N-[4-[4-amino-7-(oxan-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-2-oxo-1-phenylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCOCC1)C1=CC=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=CC=C1)=O WRADGJQBDXJRIT-UHFFFAOYSA-N 0.000 claims 1
- GPNOEUDRIWKLGC-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-hydroxyethyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]-3-fluorophenyl]-1-(4-fluorophenyl)-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)CCO)C1=C(C=C(C=C1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=C(C=C1)F)=O)F GPNOEUDRIWKLGC-UHFFFAOYSA-N 0.000 claims 1
- ZDLYCRBETASLAJ-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-hydroxyethyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]-3-fluorophenyl]-2-oxo-1-phenylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)CCO)C1=C(C=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=CC=C1)=O)F ZDLYCRBETASLAJ-UHFFFAOYSA-N 0.000 claims 1
- NNTAENHFVLQVTG-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-hydroxyethyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-1-(4-fluorophenyl)-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)CCO)C1=CC=C(C=C1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=C(C=C1)F)=O NNTAENHFVLQVTG-UHFFFAOYSA-N 0.000 claims 1
- WDXBRUHVKWGDOP-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-hydroxyethyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)CCO)C1=CC=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=C(C=C1)F)=O WDXBRUHVKWGDOP-UHFFFAOYSA-N 0.000 claims 1
- DGOGREBGMZWKCT-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-hydroxyethyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-2-oxo-1-phenylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)CCO)C1=CC=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=CC=C1)=O DGOGREBGMZWKCT-UHFFFAOYSA-N 0.000 claims 1
- AWMRXNYJPYBABO-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methoxyethyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]-3-fluorophenyl]-2-oxo-1-phenylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)CCOC)C1=C(C=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=CC=C1)=O)F AWMRXNYJPYBABO-UHFFFAOYSA-N 0.000 claims 1
- QEPUHXTUGSVGOF-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methoxyethyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)CCOC)C1=CC=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=C(C=C1)F)=O QEPUHXTUGSVGOF-UHFFFAOYSA-N 0.000 claims 1
- KQVZUBPWFJXMKN-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methoxyethyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-2-oxo-1-phenylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)CCOC)C1=CC=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=CC=C1)=O KQVZUBPWFJXMKN-UHFFFAOYSA-N 0.000 claims 1
- PNOYDYDKHRZGJD-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-1-(5-fluoropyridin-3-yl)-5,6-dimethyl-2-oxopyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C=1C(N(C(=C(C=1)C)C)C=1C=NC=C(C=1)F)=O PNOYDYDKHRZGJD-UHFFFAOYSA-N 0.000 claims 1
- RTQKZBQTKQUQFE-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-1-(5-fluoropyridin-3-yl)-6-methyl-2-oxo-5-(1,3-thiazol-4-yl)pyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C=1C(N(C(=C(C=1)C=1N=CSC=1)C)C=1C=NC=C(C=1)F)=O RTQKZBQTKQUQFE-UHFFFAOYSA-N 0.000 claims 1
- INCLUHXJYYFKBR-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-1-cyclopropyl-2,4-dioxo-3-phenylpyrimidine-5-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C=1C(N(C(N(C=1)C1CC1)=O)C1=CC=CC=C1)=O INCLUHXJYYFKBR-UHFFFAOYSA-N 0.000 claims 1
- LMVTWQWJLDGLDK-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-1-cyclopropyl-2,4-dioxo-3-pyridin-3-ylpyrimidine-5-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C=1C(N(C(N(C=1)C1CC1)=O)C=1C=NC=CC=1)=O LMVTWQWJLDGLDK-UHFFFAOYSA-N 0.000 claims 1
- HPMRGEUXGIDRHY-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-1-cyclopropyl-6-methyl-4-oxo-5-pyridin-2-ylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C=1C(C(=C(N(C=1)C1CC1)C)C1=NC=CC=C1)=O HPMRGEUXGIDRHY-UHFFFAOYSA-N 0.000 claims 1
- ICWGNNCQWSWBRG-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-1-cyclopropyl-6-methyl-5-(1,3-oxazol-2-yl)-4-oxopyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C1=CN(C(=C(C1=O)C=1OC=CN=1)C)C1CC1 ICWGNNCQWSWBRG-UHFFFAOYSA-N 0.000 claims 1
- CSINNIKEQPTXBQ-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-1-cyclopropyl-6-methyl-5-(2-methylpyridin-3-yl)-4-oxopyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C=1C(C(=C(N(C=1)C1CC1)C)C=1C(=NC=CC=1)C)=O CSINNIKEQPTXBQ-UHFFFAOYSA-N 0.000 claims 1
- YBXWUVFZDRSTIV-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-2-oxo-1-phenyl-6-pyridin-2-ylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C1=CC=C(N(C1=O)C1=CC=CC=C1)C1=NC=CC=C1 YBXWUVFZDRSTIV-UHFFFAOYSA-N 0.000 claims 1
- FAPRLJWBIKQLPC-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-3-(1,4-dimethylpyrazol-3-yl)-2,4-dioxo-1-propan-2-ylpyrimidine-5-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C=1C(N(C(N(C=1)C(C)C)=O)C1=NN(C=C1C)C)=O FAPRLJWBIKQLPC-UHFFFAOYSA-N 0.000 claims 1
- HKOWJECZABVSBF-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-3-(1-methylpyrazol-3-yl)-2,4-dioxo-1-propan-2-ylpyrimidine-5-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C=1C(N(C(N(C=1)C(C)C)=O)C1=NN(C=C1)C)=O HKOWJECZABVSBF-UHFFFAOYSA-N 0.000 claims 1
- IMHPXAIWFQNXKF-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-3-(1-methylpyrazol-4-yl)-2,4-dioxo-1-propan-2-ylpyrimidine-5-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C=1C(N(C(N(C=1)C(C)C)=O)C=1C=NN(C=1)C)=O IMHPXAIWFQNXKF-UHFFFAOYSA-N 0.000 claims 1
- NSTWZAWVSNQWFD-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-3-(3-cyanophenyl)-2,4-dioxo-1-propan-2-ylpyrimidine-5-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C=1C(N(C(N(C=1)C(C)C)=O)C1=CC(=CC=C1)C#N)=O NSTWZAWVSNQWFD-UHFFFAOYSA-N 0.000 claims 1
- SBCZVXIAPCZORV-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-3-(5-methyl-1,2-oxazol-3-yl)-2,4-dioxo-1-propan-2-ylpyrimidine-5-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C=1C(N(C(N(C=1)C(C)C)=O)C1=NOC(=C1)C)=O SBCZVXIAPCZORV-UHFFFAOYSA-N 0.000 claims 1
- VRBCYHMHHGOSNK-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-3-cyclohexyl-2,4-dioxo-1-propan-2-ylpyrimidine-5-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C=1C(N(C(N(C=1)C(C)C)=O)C1CCCCC1)=O VRBCYHMHHGOSNK-UHFFFAOYSA-N 0.000 claims 1
- VVPHXAHTGBYZOO-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-5,6-dimethyl-2-oxo-1-pyridin-3-ylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C=1C(N(C(=C(C=1)C)C)C=1C=NC=CC=1)=O VVPHXAHTGBYZOO-UHFFFAOYSA-N 0.000 claims 1
- UVGHWODZUAVXDM-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-5-(3-cyanophenyl)-6-methyl-4-oxo-1-propan-2-ylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C1=CN(C(=C(C1=O)C1=CC(=CC=C1)C#N)C)C(C)C UVGHWODZUAVXDM-UHFFFAOYSA-N 0.000 claims 1
- OVAYNUYATYARHI-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-5-(5-fluoropyridin-3-yl)-6-methyl-4-oxo-1-propan-2-ylpyridine-3-carboxamide Chemical compound CC(C)N1C=C(C(=O)NC2=CC=C(C=C2)C2=C3N(N=CN=C3N)C(=C2)C2CCN(CC2)C(=O)C(C)C)C(=O)C(=C1C)C1=CN=CC(F)=C1 OVAYNUYATYARHI-UHFFFAOYSA-N 0.000 claims 1
- RHSNGISAKYAVDE-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-5-(cyanomethyl)-1-(5-fluoropyridin-3-yl)-6-methyl-2-oxopyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C=1C(N(C(=C(C=1)CC#N)C)C=1C=NC=C(C=1)F)=O RHSNGISAKYAVDE-UHFFFAOYSA-N 0.000 claims 1
- QRIQJZZWVZTBHA-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-5-(difluoromethyl)-6-methyl-2-oxo-1-pyridin-2-ylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C=1C(N(C(=C(C=1)C(F)F)C)C1=NC=CC=C1)=O QRIQJZZWVZTBHA-UHFFFAOYSA-N 0.000 claims 1
- WBJHPKNWHXGIEH-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-5-bromo-6-(methoxymethyl)-2-oxo-1-phenylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C=1C(N(C(=C(C=1)Br)COC)C1=CC=CC=C1)=O WBJHPKNWHXGIEH-UHFFFAOYSA-N 0.000 claims 1
- LQWBLHVQPPKLHS-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-5-bromo-6-methyl-2-oxo-1-pyridin-2-ylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C=1C(N(C(=C(C=1)Br)C)C1=NC=CC=C1)=O LQWBLHVQPPKLHS-UHFFFAOYSA-N 0.000 claims 1
- WYXCSEHCHVZEPU-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-5-bromo-6-methyl-2-oxo-1-pyridin-3-ylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C=1C(N(C(=C(C=1)Br)C)C=1C=NC=CC=1)=O WYXCSEHCHVZEPU-UHFFFAOYSA-N 0.000 claims 1
- UJDNQJFCHYXCBL-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-5-chloro-6-methyl-2-oxo-1-pyridin-2-ylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C=1C(N(C(=C(C=1)Cl)C)C1=NC=CC=C1)=O UJDNQJFCHYXCBL-UHFFFAOYSA-N 0.000 claims 1
- HOODYPQSDBBQKD-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-5-chloro-6-methyl-2-oxo-1-pyridin-3-ylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C=1C(N(C(=C(C=1)Cl)C)C=1C=NC=CC=1)=O HOODYPQSDBBQKD-UHFFFAOYSA-N 0.000 claims 1
- VVGJPTXPAMARLF-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-5-cyano-6-(ethoxymethyl)-2-oxo-1-phenylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C=1C(N(C(=C(C=1)C#N)COCC)C1=CC=CC=C1)=O VVGJPTXPAMARLF-UHFFFAOYSA-N 0.000 claims 1
- FBMNZQNKRGWDOR-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-5-cyano-6-methyl-2-oxo-1-phenylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C=1C(N(C(=C(C=1)C#N)C)C1=CC=CC=C1)=O FBMNZQNKRGWDOR-UHFFFAOYSA-N 0.000 claims 1
- XVMKDIBPZRMTGI-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-5-methyl-2-oxo-1-phenyl-6-pyridin-3-ylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C1=CC(=C(N(C1=O)C1=CC=CC=C1)C=1C=NC=CC=1)C XVMKDIBPZRMTGI-UHFFFAOYSA-N 0.000 claims 1
- DRFSMWIGPWLYCE-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-6-(6-methylpyridin-3-yl)-2-oxo-1-phenylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C1=CC=C(N(C1=O)C1=CC=CC=C1)C=1C=NC(=CC=1)C DRFSMWIGPWLYCE-UHFFFAOYSA-N 0.000 claims 1
- NIIATQWOFXNHKI-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-6-methyl-2-oxo-1-phenyl-5-pyrimidin-2-ylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C=1C(N(C(=C(C=1)C1=NC=CC=N1)C)C1=CC=CC=C1)=O NIIATQWOFXNHKI-UHFFFAOYSA-N 0.000 claims 1
- FIJMVZSPQNZCOR-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-6-methyl-5-(1,3-oxazol-2-yl)-2-oxo-1-pyridin-2-ylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C=1C(N(C(=C(C=1)C=1OC=CN=1)C)C1=NC=CC=C1)=O FIJMVZSPQNZCOR-UHFFFAOYSA-N 0.000 claims 1
- QCEVKAGWYUDUQC-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-6-methyl-5-(1-methylpyrazol-3-yl)-2-oxo-1-pyridin-2-ylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C=1C(N(C(=C(C=1)C1=NN(C=C1)C)C)C1=NC=CC=C1)=O QCEVKAGWYUDUQC-UHFFFAOYSA-N 0.000 claims 1
- GUBJZSVCAQTUBA-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-6-methyl-5-(1-methylpyrazol-3-yl)-2-oxo-1-pyridin-3-ylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C=1C(N(C(=C(C=1)C1=NN(C=C1)C)C)C=1C=NC=CC=1)=O GUBJZSVCAQTUBA-UHFFFAOYSA-N 0.000 claims 1
- GYYPMRXXVODAHF-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-6-methyl-5-(1-methylpyrazol-4-yl)-2-oxo-1-phenylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C=1C(N(C(=C(C=1)C=1C=NN(C=1)C)C)C1=CC=CC=C1)=O GYYPMRXXVODAHF-UHFFFAOYSA-N 0.000 claims 1
- QGYPFGINBOTMPW-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-6-methyl-5-(1-methylpyrazol-4-yl)-2-oxo-1-pyridin-3-ylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C=1C(N(C(=C(C=1)C=1C=NN(C=1)C)C)C=1C=NC=CC=1)=O QGYPFGINBOTMPW-UHFFFAOYSA-N 0.000 claims 1
- NPZAVWSUKPDXON-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-6-methyl-5-(2-methylpyrazol-3-yl)-2-oxo-1-pyridin-2-ylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C=1C(N(C(=C(C=1)C1=CC=NN1C)C)C1=NC=CC=C1)=O NPZAVWSUKPDXON-UHFFFAOYSA-N 0.000 claims 1
- ZFDMPRUIDYFTHE-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-6-methyl-5-(2-methylpyrazol-3-yl)-2-oxo-1-pyridin-3-ylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C=1C(N(C(=C(C=1)C1=CC=NN1C)C)C=1C=NC=CC=1)=O ZFDMPRUIDYFTHE-UHFFFAOYSA-N 0.000 claims 1
- SVQLYPNPTZVLCF-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-6-methyl-5-(2-methylpyrazol-3-yl)-4-oxo-1-propan-2-ylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C1=CN(C(=C(C1=O)C1=CC=NN1C)C)C(C)C SVQLYPNPTZVLCF-UHFFFAOYSA-N 0.000 claims 1
- JKTDOECEXXHAHP-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(2-methylpropanoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-6-methyl-5-morpholin-4-yl-2-oxo-1-phenylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(C(C)C)=O)C1=CC=C(C=C1)NC(=O)C=1C(N(C(=C(C=1)N1CCOCC1)C)C1=CC=CC=C1)=O JKTDOECEXXHAHP-UHFFFAOYSA-N 0.000 claims 1
- XQAVHPYTFJJMAT-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(dimethylcarbamoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]-3-fluorophenyl]-2-oxo-1-phenylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(=O)N(C)C)C1=C(C=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=CC=C1)=O)F XQAVHPYTFJJMAT-UHFFFAOYSA-N 0.000 claims 1
- GGVGDODWBCTHMO-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(dimethylcarbamoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(=O)N(C)C)C1=CC=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=C(C=C1)F)=O GGVGDODWBCTHMO-UHFFFAOYSA-N 0.000 claims 1
- UBJCWZPYNKJGNN-UHFFFAOYSA-N N-[4-[4-amino-7-[1-(dimethylcarbamoyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-2-oxo-1-phenylpyridine-3-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(=O)N(C)C)C1=CC=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=CC=C1)=O UBJCWZPYNKJGNN-UHFFFAOYSA-N 0.000 claims 1
- UOWBILPOXAHWAD-UHFFFAOYSA-N N-[4-[4-amino-7-[4-(dimethylamino)cyclohexyl]pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-2,4-dioxo-3-phenyl-1-propan-2-ylpyrimidine-5-carboxamide Chemical compound NC1=NC=NN2C1=C(C=C2C1CCC(CC1)N(C)C)C1=CC=C(C=C1)NC(=O)C=1C(N(C(N(C=1)C(C)C)=O)C1=CC=CC=C1)=O UOWBILPOXAHWAD-UHFFFAOYSA-N 0.000 claims 1
- VQHVYKXPWUBCRQ-UHFFFAOYSA-N N-[4-[7-(1-acetylpiperidin-4-yl)-4-aminopyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide Chemical compound C(C)(=O)N1CCC(CC1)C1=CC(=C2C(=NC=NN21)N)C1=CC=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=C(C=C1)F)=O VQHVYKXPWUBCRQ-UHFFFAOYSA-N 0.000 claims 1
- ZRLFZFXBBUSCFN-UHFFFAOYSA-N N-[4-[7-(1-acetylpiperidin-4-yl)-4-aminopyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl]-2-oxo-1-phenylpyridine-3-carboxamide Chemical compound C(C)(=O)N1CCC(CC1)C1=CC(=C2C(=NC=NN21)N)C1=CC=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=CC=C1)=O ZRLFZFXBBUSCFN-UHFFFAOYSA-N 0.000 claims 1
- OXPQSGRKFNVPAM-WGSAOQKQSA-N NC1=NC=NN2C1=C(C=C2[C@@H]1CC[C@H](CC1)C#N)C1=C(C=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=C(C=C1)F)=O)F Chemical compound NC1=NC=NN2C1=C(C=C2[C@@H]1CC[C@H](CC1)C#N)C1=C(C=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=C(C=C1)F)=O)F OXPQSGRKFNVPAM-WGSAOQKQSA-N 0.000 claims 1
- PHPKMXFRPJBGSR-MXVIHJGJSA-N NC1=NC=NN2C1=C(C=C2[C@@H]1CC[C@H](CC1)C#N)C1=C(C=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=CC=C1)=O)F Chemical compound NC1=NC=NN2C1=C(C=C2[C@@H]1CC[C@H](CC1)C#N)C1=C(C=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=CC=C1)=O)F PHPKMXFRPJBGSR-MXVIHJGJSA-N 0.000 claims 1
- HVMCHMJVEKCRCI-XUTJKUGGSA-N NC1=NC=NN2C1=C(C=C2[C@@H]1CC[C@H](CC1)C#N)C1=CC=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=C(C=C1)F)=O Chemical compound NC1=NC=NN2C1=C(C=C2[C@@H]1CC[C@H](CC1)C#N)C1=CC=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=C(C=C1)F)=O HVMCHMJVEKCRCI-XUTJKUGGSA-N 0.000 claims 1
- KZRUTRKOHDQVNC-AQYVVDRMSA-N NC1=NC=NN2C1=C(C=C2[C@@H]1CC[C@H](CC1)C#N)C1=CC=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=CC=C1)=O Chemical compound NC1=NC=NN2C1=C(C=C2[C@@H]1CC[C@H](CC1)C#N)C1=CC=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=CC=C1)=O KZRUTRKOHDQVNC-AQYVVDRMSA-N 0.000 claims 1
- ONSJKYVPJNEILC-XGAFWQRZSA-N NC1=NC=NN2C1=C(C=C2[C@@H]1CC[C@H](CC1)O)C1=C(C=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=CC=C1)=O)F Chemical compound NC1=NC=NN2C1=C(C=C2[C@@H]1CC[C@H](CC1)O)C1=C(C=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=CC=C1)=O)F ONSJKYVPJNEILC-XGAFWQRZSA-N 0.000 claims 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000005678 Rhabdomyoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010043276 Teratoma Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims 1
- 201000006966 adult T-cell leukemia Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- MPVDXIMFBOLMNW-UHFFFAOYSA-N chembl1615565 Chemical compound OC1=CC=C2C=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=C1N=NC1=CC=CC=C1 MPVDXIMFBOLMNW-UHFFFAOYSA-N 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010016629 fibroma Diseases 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- WHJOYBCBROPEDL-UHFFFAOYSA-N methyl 4-[4-amino-5-[2-fluoro-4-[(2-oxo-1-phenylpyridine-3-carbonyl)amino]phenyl]pyrrolo[2,1-f][1,2,4]triazin-7-yl]piperidine-1-carboxylate Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(=O)OC)C1=C(C=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=CC=C1)=O)F WHJOYBCBROPEDL-UHFFFAOYSA-N 0.000 claims 1
- LLGTZIXASKDKRV-UHFFFAOYSA-N methyl 4-[4-amino-5-[4-[(2-oxo-1-phenylpyridine-3-carbonyl)amino]phenyl]pyrrolo[2,1-f][1,2,4]triazin-7-yl]piperidine-1-carboxylate Chemical compound NC1=NC=NN2C1=C(C=C2C1CCN(CC1)C(=O)OC)C1=CC=C(C=C1)NC(=O)C=1C(N(C=CC=1)C1=CC=CC=C1)=O LLGTZIXASKDKRV-UHFFFAOYSA-N 0.000 claims 1
- 208000009091 myxoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 125000004287 oxazol-2-yl group Chemical group [H]C1=C([H])N=C(*)O1 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662314066P | 2016-03-28 | 2016-03-28 | |
US201662362934P | 2016-07-15 | 2016-07-15 | |
US201662438750P | 2016-12-23 | 2016-12-23 | |
EP17715620.5A EP3436461B1 (de) | 2016-03-28 | 2017-03-27 | Pyrrolotriazinverbindungen als tam-inhibitoren |
PCT/US2017/024270 WO2017172596A1 (en) | 2016-03-28 | 2017-03-27 | Pyrrolotriazine compounds as tam inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20231614T1 true HRP20231614T1 (hr) | 2024-03-15 |
Family
ID=58489114
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20231614TT HRP20231614T1 (hr) | 2016-03-28 | 2017-03-27 | Spojevi pirolotriazina kao tam inhibitori |
Country Status (31)
Country | Link |
---|---|
US (5) | US9981975B2 (de) |
EP (2) | EP3436461B1 (de) |
JP (3) | JP7034084B2 (de) |
KR (3) | KR102558066B1 (de) |
CN (3) | CN114456176B (de) |
AU (3) | AU2017241524B2 (de) |
CA (1) | CA3019145A1 (de) |
CL (1) | CL2018002759A1 (de) |
CO (1) | CO2018011550A2 (de) |
CR (1) | CR20180516A (de) |
DK (1) | DK3436461T3 (de) |
EC (3) | ECSP18081153A (de) |
ES (1) | ES2967866T3 (de) |
FI (1) | FI3436461T3 (de) |
HR (1) | HRP20231614T1 (de) |
HU (1) | HUE064656T2 (de) |
IL (2) | IL293496B2 (de) |
LT (1) | LT3436461T (de) |
MD (1) | MD3436461T2 (de) |
MX (1) | MX2018011792A (de) |
MY (1) | MY202022A (de) |
PE (1) | PE20190175A1 (de) |
PH (1) | PH12018502102A1 (de) |
PL (1) | PL3436461T3 (de) |
PT (1) | PT3436461T (de) |
RS (1) | RS65129B1 (de) |
SG (2) | SG11201808582RA (de) |
SI (1) | SI3436461T1 (de) |
TW (2) | TWI828027B (de) |
UA (1) | UA123785C2 (de) |
WO (1) | WO2017172596A1 (de) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017027717A1 (en) | 2015-08-12 | 2017-02-16 | Incyte Corporation | Bicyclic fused pyrimidine compounds as tam inhibitors |
WO2017035366A1 (en) | 2015-08-26 | 2017-03-02 | Incyte Corporation | Pyrrolopyrimidine derivatives as tam inhibitors |
SG11201808582RA (en) | 2016-03-28 | 2018-10-30 | Incyte Corp | Pyrrolotriazine compounds as tam inhibitors |
US12023319B2 (en) | 2016-12-23 | 2024-07-02 | Bayer Pharma Aktiengesellschaft | Carboxylic acid aromatic amides |
JOP20190156B1 (ar) | 2016-12-23 | 2023-09-17 | Bayer Pharma AG | أميدات عطرية لحمض الكربوكسيليك بصفتها مضادات لمستقبلة البراديكينين b1 |
JP7156287B2 (ja) | 2017-08-23 | 2022-10-19 | 小野薬品工業株式会社 | Axl阻害剤を有効成分として含むがん治療剤 |
PT3687996T (pt) * | 2017-09-27 | 2022-01-21 | Incyte Corp | Sais de derivados de pirrolotriazina úteis como inibidores de tam |
EP3695839A4 (de) | 2017-10-13 | 2021-07-14 | ONO Pharmaceutical Co., Ltd. | Therapeutisches mittel mit axl-inhibitor als wirkstoff für solide tumore |
US20210177828A1 (en) * | 2018-01-17 | 2021-06-17 | Nanjing Transthera Biosciences Co., Ltd. | Tam family kinase /and csf1r kinase inhibitor and use thereof |
US11618753B2 (en) | 2018-01-26 | 2023-04-04 | Bristol-Myers Squibb Company | Aminopyrrolotriazines as kinase inhibitors |
CN110627796B (zh) * | 2018-06-21 | 2022-07-12 | 北京越之康泰生物医药科技有限公司 | 含氮杂环类衍生物及其在医药上的应用 |
US11241438B2 (en) * | 2018-06-29 | 2022-02-08 | Incyte Corporation | Formulations of an AXL/MER inhibitor |
UY38349A (es) | 2018-08-30 | 2020-03-31 | Array Biopharma Inc | Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met |
CN111689991B (zh) * | 2019-03-13 | 2023-06-09 | 习峰 | 取代的杂芳基化合物及其组合物和用途 |
CN110156836A (zh) * | 2019-06-10 | 2019-08-23 | 成家钢 | 一种环丙基羰基亚甲基三苯基磷的制备方法 |
WO2021020362A1 (ja) * | 2019-07-29 | 2021-02-04 | 武田薬品工業株式会社 | 複素環化合物 |
CN112409361B (zh) * | 2019-08-23 | 2022-08-16 | 山东轩竹医药科技有限公司 | Tam抑制剂及其用途 |
CN112457295B (zh) * | 2019-09-06 | 2022-07-26 | 中国科学院上海药物研究所 | 具有Axl与c-Met激酶抑制活性的化合物及其制备和应用 |
CN113336758B (zh) * | 2020-03-03 | 2022-08-19 | 北京桦冠医药科技有限公司 | 化合物7-碘吡咯并[2,1-f][1,2,4]三嗪-4-胺的一种新合成方法 |
KR20230017165A (ko) | 2020-03-06 | 2023-02-03 | 인사이트 코포레이션 | Axl/mer 및 pd-1/pd-l1 억제제를 포함하는 병행 요법 |
CN111233870A (zh) * | 2020-03-11 | 2020-06-05 | 中国科学技术大学 | 用于快速制备瑞德西韦药物中间体的方法 |
WO2021233236A1 (zh) * | 2020-05-18 | 2021-11-25 | 北京范恩柯尔生物科技有限公司 | 取代的杂芳基化合物及其组合物和用途 |
CN113912628B (zh) * | 2020-07-10 | 2023-05-02 | 北京范恩柯尔生物科技有限公司 | 三嗪类化合物及其组合物和用途 |
WO2022166610A1 (zh) * | 2021-02-05 | 2022-08-11 | 四川科伦博泰生物医药股份有限公司 | 一类哒嗪酮杂环化合物及其制备方法和用途 |
WO2023016296A1 (zh) * | 2021-08-12 | 2023-02-16 | 四川科伦博泰生物医药股份有限公司 | 一类杂环化合物及其制备方法和用途 |
TW202330519A (zh) * | 2021-09-29 | 2023-08-01 | 香港商德琪研發有限公司 | 作為tam抑制劑的吡唑并吡啶化合物 |
WO2023155886A1 (en) * | 2022-02-17 | 2023-08-24 | Shanghai Antengene Corporation Limited | Pyrazolopyridine compounds as tam inhibitors |
WO2024054793A1 (en) | 2022-09-09 | 2024-03-14 | University Of Rochester | Inhibition of efferocytosis as a treatment to prevent bone loss and increase bone density and strength |
Family Cites Families (206)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5156840A (en) | 1982-03-09 | 1992-10-20 | Cytogen Corporation | Amine-containing porphyrin derivatives |
US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
US4908056A (en) | 1986-04-25 | 1990-03-13 | E. I. Du Pont De Nemours And Company | Heterocyclic acyl sulfonamides |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
EP0352575A3 (de) | 1988-07-28 | 1991-08-21 | Bayer Ag | Substituierte anellierte Pyrrole |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
EP1136556B1 (de) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
IT1269176B (it) | 1994-01-11 | 1997-03-21 | Isagro Srl | Eterobicicli ad attivita' fungicida |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
CA2229043C (en) | 1995-08-18 | 2016-06-07 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
JP2001520268A (ja) | 1997-10-14 | 2001-10-30 | ザ、プロクター、エンド、ギャンブル、カンパニー | 中鎖分枝鎖界面活性剤を包含する硬質表面クリーニング組成物 |
US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
PL354241A1 (en) | 1999-09-17 | 2003-12-29 | Abbott Gmbh & Co.Kgabbott Gmbh & Co.Kg | Kinase inhibitors as therapeutic agents |
CN1623984A (zh) | 1999-12-27 | 2005-06-08 | 日本烟草产业株式会社 | 稠环化合物及其药物用途 |
US6770666B2 (en) | 1999-12-27 | 2004-08-03 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs |
CA2413330A1 (en) | 2000-06-28 | 2002-01-03 | Smithkline Beecham P.L.C. | Wet milling process |
PL363991A1 (en) | 2001-04-06 | 2004-11-29 | Wyeth | Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil |
AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
AU2003272175A1 (en) | 2002-10-21 | 2004-05-04 | Aprea Ab | Reactivation of wild type p53 in human tumour cells by a low molecular weight compound |
US7824851B2 (en) | 2002-11-15 | 2010-11-02 | Idenix Pharmaceuticals, Inc. | 2′-branched nucleosides and Flaviviridae mutation |
ES2897506T3 (es) | 2003-01-09 | 2022-03-01 | Macrogenics Inc | Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos |
US20050079574A1 (en) | 2003-01-16 | 2005-04-14 | Genentech, Inc. | Synthetic antibody phage libraries |
US20050008625A1 (en) | 2003-02-13 | 2005-01-13 | Kalobios, Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
WO2004082606A2 (en) | 2003-03-13 | 2004-09-30 | Synta Pharmaceuticals Corp. | Fused pyrrole compounds |
JP2006520796A (ja) | 2003-03-17 | 2006-09-14 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼインヒビター |
NZ544486A (en) | 2003-06-13 | 2009-04-30 | Biogen Idec Inc | Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof |
FR2857966A1 (fr) | 2003-07-24 | 2005-01-28 | Aventis Pharma Sa | Produits aryl-heteroaromatiques, compositions les contenant et utilisation |
WO2005018572A2 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
US20050203063A1 (en) | 2003-09-12 | 2005-09-15 | Raymond Deshaies | Proteasome pathway inhibitors and related methods |
US7306631B2 (en) | 2004-03-30 | 2007-12-11 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
UY28931A1 (es) | 2004-06-03 | 2005-12-30 | Bayer Pharmaceuticals Corp | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis |
AR053090A1 (es) * | 2004-07-20 | 2007-04-25 | Osi Pharm Inc | Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos |
US20070015771A1 (en) | 2004-07-29 | 2007-01-18 | Threshold Pharmaceuticals, Inc. | Lonidamine analogs |
US20070043057A1 (en) | 2005-02-09 | 2007-02-22 | Threshold Pharmaceuticals, Inc. | Lonidamine analogs |
UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
RU2007123675A (ru) | 2004-11-24 | 2008-12-27 | Новартис АГ (CH) | Комбинации ингибиторов jak |
WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
JP5116687B2 (ja) | 2005-11-02 | 2013-01-09 | バイエル・ファルマ・アクチェンゲゼルシャフト | がんおよび他の過剰増殖性疾患の処置のためのピロロ[2,1−f][1,2,4]トリアジン−4−イルアミンIGF−1Rキナーゼ阻害剤 |
MY148491A (en) | 2005-11-17 | 2013-04-30 | Osi Pharm Inc | FUSED BICYCLIC mTOR INHIBITORS |
US7514435B2 (en) | 2005-11-18 | 2009-04-07 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
PE20070855A1 (es) | 2005-12-02 | 2007-10-14 | Bayer Pharmaceuticals Corp | Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas |
JP5193876B2 (ja) | 2005-12-02 | 2013-05-08 | バイエル・ヘルスケア・エルエルシー | オーロラキナーゼの阻害により癌を処置するために有用なピロロトリアジン誘導体 |
JP5249776B2 (ja) | 2005-12-02 | 2013-07-31 | バイエル・ヘルスケア・エルエルシー | 過剰増殖性疾患および血管新生と関連する疾患を処置するために有用な置換された4−アミノ−ピロロトリアジン誘導体 |
MY159449A (en) | 2005-12-13 | 2017-01-13 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
CA2633035C (en) | 2005-12-15 | 2016-05-10 | Rigel Pharmaceuticals, Inc. | Kinase inhibitors and their uses |
CA2635231C (en) | 2005-12-29 | 2014-07-15 | Abbott Laboratories | Protein kinase inhibitors |
JP5313875B2 (ja) | 2006-04-12 | 2013-10-09 | バーテックス ファーマシューティカルズ インコーポレイテッド | 増殖性疾患の処置のためのタンパク質キナーゼplk1の阻害剤として有用な4,5−ジヒドロ−[1,2,4]トリアゾロ[4,3−f]プテリジン |
PL2010528T3 (pl) | 2006-04-19 | 2018-03-30 | Novartis Ag | 6-0-podstawione związki benzoksazolowe i benzotiazolowe i sposoby hamowania sygnalizacji csf-1r |
JP2009536161A (ja) | 2006-04-25 | 2009-10-08 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
KR20090031544A (ko) | 2006-06-29 | 2009-03-26 | 쉐링 코포레이션 | 치환된 비사이클릭 및 트리사이클릭 트롬빈 수용체 길항제 |
WO2008012635A2 (en) | 2006-07-26 | 2008-01-31 | Pfizer Products Inc. | Amine derivatives useful as anticancer agents |
WO2008045978A1 (en) | 2006-10-10 | 2008-04-17 | Rigel Pharmaceuticals, Inc. | Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors |
JP5572388B2 (ja) * | 2006-11-22 | 2014-08-13 | インサイト・コーポレイション | キナーゼ阻害剤としてのイミダゾトリアジンおよびイミダゾピリミジン |
JP2010512317A (ja) | 2006-12-07 | 2010-04-22 | シェーリング コーポレイション | pH感受性マトリクス処方物 |
EP2102210B1 (de) | 2006-12-14 | 2011-02-09 | Vertex Pharmceuticals Incorporated | Als proteinkinaseinhibitoren geeignete verbindungen |
AU2007342005A1 (en) | 2006-12-29 | 2008-07-10 | Rigel Pharmaceuticals, Inc. | N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors |
US7709482B2 (en) | 2006-12-29 | 2010-05-04 | Rigel Pharmaceuticals, Inc. | Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors |
ES2406930T3 (es) | 2006-12-29 | 2013-06-10 | Rigel Pharmaceuticals, Inc. | Triazoles sustituidos con arilo bicíclico y heteroarilo bicíclico útiles como inhibidores de AXL |
CN101611046A (zh) | 2007-01-12 | 2009-12-23 | 拜奥克里斯特制药公司 | 抗病毒的核苷类似物 |
US8168415B2 (en) | 2007-02-07 | 2012-05-01 | The Regents Of The University Of Colorado | Axl fusion proteins as Axl tyrosine kinase inhibitors |
US8124759B2 (en) | 2007-05-09 | 2012-02-28 | Abbott Laboratories | Inhibitors of protein kinases |
AU2008251555B2 (en) | 2007-05-10 | 2012-08-30 | Biocryst Pharmaceuticals, Inc. | Tetrahydrofuro [3 4-D] dioxolane compounds for use in the treatment of viral infections and cancer |
EP2173338A1 (de) | 2007-07-06 | 2010-04-14 | OSI Pharmaceuticals, Inc. | Kombinations-antikrebstherapie |
EP2178563A2 (de) | 2007-07-06 | 2010-04-28 | OSI Pharmaceuticals, Inc. | Kombinationskrebstherapie mit einem hemmer sowohl für mtorc1 als auch für mtorc2 |
EP2190849B1 (de) | 2007-08-15 | 2013-11-20 | Vertex Pharmceuticals Incorporated | 4-(9-(3,3-difluorocyclopentyl)-5,7,7-trimethyl-6-oxo-6,7,8,9-tetrahydro-5h-pyrimido[4,5-b[1,4]diazepin-2-ylamino)-3-methoxybenzamid derivate als inhibitoren der menschlichen protein kinasen plk1 bis plk4 zur behandlung von proliferativen erkrankungen |
WO2009042543A1 (en) | 2007-09-25 | 2009-04-02 | Bayer Healthcare Llc | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase |
GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
CN101910158A (zh) | 2007-10-25 | 2010-12-08 | 阿斯利康(瑞典)有限公司 | 可用于治疗细胞增殖性病症的吡啶衍生物和吡嗪衍生物 |
WO2009054864A1 (en) | 2007-10-26 | 2009-04-30 | Rigel Pharmaceuticals, Inc. | Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
DE102007051762A1 (de) | 2007-10-30 | 2009-05-07 | Bayer Healthcare Ag | Substituierte Pyrrolotriazine und ihre Verwendung |
EP2231656A1 (de) | 2007-12-19 | 2010-09-29 | Amgen Inc. | Kondensierte pyridin-, pyrimidin- und triazinverbindungen als zellzyklushemmer |
AR070127A1 (es) | 2008-01-11 | 2010-03-17 | Novartis Ag | Pirrolo - pirimidinas y pirrolo -piridinas |
EA018144B1 (ru) | 2008-03-19 | 2013-05-30 | Оси Фармасьютикалз, Инк. | СОЛЕВЫЕ ФОРМЫ ИНГИБИТОРА mTOR |
US9206130B2 (en) | 2008-04-16 | 2015-12-08 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Quinoline derivatives as AXL kinase inhibitors |
BRPI0910455B8 (pt) | 2008-04-23 | 2021-05-25 | Gilead Sciences Inc | análogos de carba-nucleosídeo 1-substituído para tratamento antiviral e composição farmacêutica que os compreende |
TWI539953B (zh) | 2008-04-28 | 2016-07-01 | 瑞波若斯治療學公司 | 用於治療乳癌之組成物和方法 |
MX346186B (es) | 2008-06-23 | 2017-03-10 | Vertex Pharma | Inhibidores de proteina cinasas. |
KR20110018376A (ko) | 2008-06-23 | 2011-02-23 | 스미또모 가가꾸 가부시키가이샤 | 조성물 및 상기 조성물을 이용하여 이루어지는 발광 소자 |
WO2010002877A2 (en) | 2008-07-03 | 2010-01-07 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
CA2730231C (en) | 2008-07-09 | 2016-10-18 | Rigel Pharmaceuticals, Inc. | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
JP5613156B2 (ja) | 2008-07-09 | 2014-10-22 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Axl阻害剤として有用な架橋二環ヘテロアリール置換トリアゾール |
WO2010014755A1 (en) | 2008-07-29 | 2010-02-04 | The Regents Of The University Of Colorado | Methods and compounds for enhancing anti-cancer therapy |
US20100075973A1 (en) | 2008-08-28 | 2010-03-25 | Takeda Pharmaceutical Company Limited | Polo-like kinase inhibitors |
JP2012506238A (ja) | 2008-10-20 | 2012-03-15 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイト | インスリン様増殖因子−1受容体キナーゼ阻害剤に対する抗がん反応を予測する生物学的マーカー |
US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
TW201035100A (en) | 2008-12-19 | 2010-10-01 | Cephalon Inc | Pyrrolotriazines as ALK and JAK2 inhibitors |
CN102307875A (zh) | 2009-02-09 | 2012-01-04 | 苏伯俭股份有限公司 | 吡咯并嘧啶基axl激酶抑制剂 |
US20100204265A1 (en) | 2009-02-09 | 2010-08-12 | Genelabs Technologies, Inc. | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections |
US20120189641A1 (en) | 2009-02-25 | 2012-07-26 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
WO2010104307A2 (ko) | 2009-03-07 | 2010-09-16 | 주식회사 메디젠텍 | 세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물 |
US8765754B2 (en) | 2009-04-29 | 2014-07-01 | Locus Pharmaceuticals, Inc. | Pyrrolotriazine compounds |
WO2010135650A1 (en) | 2009-05-22 | 2010-11-25 | Incyte Corporation | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS |
AR077280A1 (es) * | 2009-06-29 | 2011-08-17 | Incyte Corp | Pirimidinonas como inhibidores de pi3k, y composiciones farmaceuticas que los comprenden |
US20120128670A1 (en) | 2009-07-31 | 2012-05-24 | OSI Pharmaceuticals, LLC | mTOR INHIBITOR AND ANGIOGENESIS INHIBITOR COMBINATION THERAPY |
AR078012A1 (es) | 2009-09-01 | 2011-10-05 | Incyte Corp | Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus |
SI2480559T1 (sl) | 2009-09-21 | 2013-10-30 | Gilead Sciences, Inc. | Postopki in intermediati za pripravo 1'-ciano-karbanukleozidnih analogov |
US8455451B2 (en) | 2009-09-21 | 2013-06-04 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
ME02656B (de) | 2009-09-21 | 2017-06-20 | Gilead Sciences Inc | 2' -fluorsubstituierte carba-nukleosidanaloga zur antiviralen behandlung |
RU2012116526A (ru) | 2009-09-25 | 2013-10-27 | Вертекс Фармасьютикалз Инкорпорейтед | Способы получения производных пиримидина, применимых в качестве ингибиторов протеинкиназы |
HUE043536T2 (hu) | 2009-10-06 | 2019-08-28 | Millennium Pharm Inc | PDK1 inhibitorként alkalmazható heterociklusos vegyületek |
EP2311809A1 (de) | 2009-10-16 | 2011-04-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Chinolinyloxyphenylsulfonamide |
US8604217B2 (en) | 2009-11-12 | 2013-12-10 | Selvita S.A. | Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent |
AR079529A1 (es) | 2009-12-18 | 2012-02-01 | Incyte Corp | Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k |
CA2787714C (en) | 2010-01-22 | 2019-04-09 | Joaquin Pastor Fernandez | Inhibitors of pi3 kinase |
PT3050882T (pt) | 2010-03-10 | 2018-04-16 | Incyte Holdings Corp | Derivados de piperidin-4-ilazetidina como inibidores de jak1 |
EP2552922A1 (de) * | 2010-03-31 | 2013-02-06 | Bristol-Myers Squibb Company | Substituierte pyrrolotriazine als proteinkinasehemmer |
CA2761074A1 (en) | 2010-05-05 | 2011-11-10 | Vertex Pharmaceuticals Incorporated | 4 substituted pyrazolopyrimidines useful as pkc-theta inhibitors |
WO2011141713A1 (en) | 2010-05-13 | 2011-11-17 | Centro Nacional De Investigaciones Oncologicas (Cnio) | New bicyclic compounds as pi3-k and mtor inhibitors |
TW201201815A (en) | 2010-05-28 | 2012-01-16 | Gilead Sciences Inc | 1'-substituted-carba-nucleoside prodrugs for antiviral treatment |
GB2480814A (en) | 2010-06-01 | 2011-12-07 | Summit Corp Plc | Compounds for the treatment of clostridium difficile-associated disease |
KR20200052384A (ko) | 2010-07-19 | 2020-05-14 | 길리애드 사이언시즈, 인코포레이티드 | 부분입체 이성질성으로 순수한 포스포라미데이트 전구약물의 제조 방법 |
ES2524356T3 (es) | 2010-07-22 | 2014-12-05 | Gilead Sciences, Inc. | Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae |
EP2423208A1 (de) | 2010-08-28 | 2012-02-29 | Lead Discovery Center GmbH | Pharmazeutisch aktive Zusammensetzungen als Axl-Hemmer |
US20120077814A1 (en) | 2010-09-10 | 2012-03-29 | Zhong Wang | Sulfonamide, sulfamate, and sulfamothioate derivatives |
TW201305185A (zh) | 2010-09-13 | 2013-02-01 | Gilead Sciences Inc | 用於抗病毒治療之2’-氟取代之碳-核苷類似物 |
CN103221412B (zh) | 2010-09-29 | 2015-08-19 | 橘生药品工业株式会社 | (氮杂)中氮茚衍生物及其药物用途 |
CN103403010A (zh) | 2010-10-08 | 2013-11-20 | 依兰制药公司 | Polo样激酶的抑制剂 |
CN103249732B (zh) | 2010-10-08 | 2016-08-10 | 生物区欧洲有限公司 | 抑制2-乙基氨甲酰氨基-1,3-苯并噻唑-5-基的细菌拓扑异构酶ii |
ITRM20100537A1 (it) | 2010-10-12 | 2012-04-12 | Consiglio Nazionale Ricerche | Aptamero inibitore del recettore tirosina chinasi axl per uso in terapia |
AU2011329734B2 (en) | 2010-11-19 | 2015-05-28 | Incyte Holdings Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
CA2818545C (en) | 2010-11-19 | 2019-04-16 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
CA2822070C (en) | 2010-12-20 | 2019-09-17 | Incyte Corporation | N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
JP6130305B2 (ja) | 2011-02-23 | 2017-05-17 | インテリカイン, エルエルシー | キナーゼ阻害剤の組み合わせおよびそれらの使用 |
EP2678016B1 (de) | 2011-02-23 | 2016-08-10 | Intellikine, LLC | Heterocyclische verbindungen und ihre verwendung |
EP2680886B1 (de) | 2011-02-28 | 2016-08-10 | Calitor Sciences, LLC | Substituierte chinolinverbindungen |
WO2012129344A1 (en) | 2011-03-23 | 2012-09-27 | Amgen Inc. | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
PT2693881T (pt) | 2011-04-01 | 2019-12-09 | Univ Utah Res Found | Análogos de n-fenilpirimidin-2-amina substituídos como inibidores da axl cinase |
US20140357651A1 (en) | 2011-05-04 | 2014-12-04 | Yi Liu | Combination pharmaceutical compositions and uses thereof |
WO2012154608A1 (en) | 2011-05-06 | 2012-11-15 | Intellikine, Llc | Reactive mtor and pi3 kinase inhibitors and uses thereof |
US9376438B2 (en) | 2011-05-17 | 2016-06-28 | Principia Biopharma, Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
PT2710005T (pt) | 2011-05-17 | 2016-11-16 | Principia Biopharma Inc | Inibidores de tirosina-quinase |
EP2710007B1 (de) | 2011-05-17 | 2019-12-11 | The Regents of The University of California | Kinase-inhibitoren |
AR086913A1 (es) | 2011-06-14 | 2014-01-29 | Novartis Ag | 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas |
ES2560611T3 (es) | 2011-06-20 | 2016-02-22 | Incyte Holdings Corporation | Derivados de fenil de azetidinilo, carboxamida de piridilo o pirazinilo como inhibidores de JAK |
SG195100A1 (en) | 2011-07-01 | 2013-12-30 | Bayer Ip Gmbh | Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors |
EP2548877A1 (de) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Gliedrige kondensierte Pyridinyl)benzamide als BTK-Inhibitoren |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
DK2751109T3 (en) | 2011-09-02 | 2017-01-23 | Incyte Holdings Corp | HETEROCYCLYLAMINES AS PI3K INHIBITORS |
JP2014526512A (ja) | 2011-09-18 | 2014-10-06 | ユーロ−セルティーク エス.エイ. | 医薬組成物 |
CN102408411B (zh) | 2011-09-19 | 2014-10-22 | 北京康辰药业股份有限公司 | 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
KR102063098B1 (ko) | 2011-10-03 | 2020-01-08 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 암 치료를 위한 피롤로피리미딘 화합물 |
EP2776441A4 (de) | 2011-11-08 | 2015-04-08 | Intellikine Llc | Behandlungsverfahren mit mehreren pharmazeutischen mitteln |
TWI562989B (en) | 2011-11-14 | 2016-12-21 | Ignyta Inc | Uracil derivatives as axl and c-met kinase inhibitors |
WO2013078440A2 (en) | 2011-11-23 | 2013-05-30 | Intellikine, Llc | Enhanced treatment regimens using mtor inhibitors |
EP2788000B1 (de) | 2011-12-06 | 2018-05-30 | Merck Sharp & Dohme Corp. | Pyrrolopyrimidine als januskinaseinhibitoren |
ES2570862T3 (es) | 2011-12-15 | 2016-05-20 | Bayer Ip Gmbh | Benzotienil-pirrolotriazinas sustituidas y usos de las mismas en el tratamiento de cáncer |
UY34484A (es) | 2011-12-15 | 2013-07-31 | Bayer Ip Gmbh | Benzotienilo-pirrolotriazinas disustituidas y sus usos |
LT2810937T (lt) | 2012-01-31 | 2017-02-10 | Daiichi Sankyo Company, Limited | Piridono darinys |
WO2013113097A1 (en) | 2012-01-31 | 2013-08-08 | Beta Pharma Canada Inc. | Cyclic molecules as bruton's tyrosine kinase inhibitors |
ES2581065T3 (es) | 2012-02-23 | 2016-08-31 | Bayer Intellectual Property Gmbh | Benzotienil-pirrolotriazinas sustituidas y usos de las mismas |
US20150057243A1 (en) | 2012-04-02 | 2015-02-26 | Northern University | Compositions and Methods for the Inhibition of Methyltransferases |
CN103373996A (zh) | 2012-04-20 | 2013-10-30 | 山东亨利医药科技有限责任公司 | 作为crth2受体拮抗剂的二并环衍生物 |
WO2013162061A1 (ja) | 2012-04-26 | 2013-10-31 | 第一三共株式会社 | 二環性ピリミジン化合物 |
TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
DK2861599T3 (da) | 2012-06-18 | 2020-03-02 | Principia Biopharma Inc | Reversible kovalente pyrrolo- eller pyrazolopyrimidiner, der er nyttige til behandling af cancer og autoimmunsygdomme |
US9505751B2 (en) | 2012-06-19 | 2016-11-29 | Sunovion Pharmaceuticals Inc. | Substituted [1,2,4]triazolo[1,5-a]pyrazines as phosphodiesterase inhibitors |
US9260436B2 (en) | 2012-06-22 | 2016-02-16 | Sumitomo Chemical Company, Limited | Fused heterocyclic compound |
US9572811B2 (en) | 2012-08-03 | 2017-02-21 | Principia Biopharma Inc. | Treatment of dry eye |
WO2014035140A2 (en) | 2012-08-30 | 2014-03-06 | Kainos Medicine, Inc. | Compounds and compositions for modulating histone methyltransferase activity |
JP6318156B2 (ja) | 2012-09-06 | 2018-04-25 | プレキシコン インコーポレーテッドPlexxikon Inc. | キナーゼをモジュレートするための化合物および方法、ならびにその指標 |
WO2014042433A2 (en) | 2012-09-14 | 2014-03-20 | Kainos Medicine, Inc. | Compounds and compositions for modulating adenosine a3 receptor activity |
CA2886240A1 (en) | 2012-09-26 | 2014-04-03 | The Regents Of The University Of California | Modulation of ire1 |
EP2909210A4 (de) | 2012-10-17 | 2016-04-06 | Merck Sharp & Dohme | 2'-disubstituierte nukleosidderivate und verfahren zur verwendung davon zur behandlung von viruserkrankungen |
EP2909209B1 (de) | 2012-10-17 | 2022-08-03 | Merck Sharp & Dohme LLC | 2'-cyan-substituierte nukleosidderivate und verfahren zur verwendung davon zur behandlung von viruserkrankungen |
US9562047B2 (en) | 2012-10-17 | 2017-02-07 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
CN104918945B (zh) | 2012-11-01 | 2018-01-05 | 因赛特公司 | 作为jak抑制剂的三环稠合噻吩衍生物 |
EP2919785A4 (de) | 2012-11-16 | 2016-10-05 | Biocryst Pharm Inc | Antivirale azazuckerhaltige nukleoside |
US9925193B2 (en) | 2012-11-20 | 2018-03-27 | Proqinase Gmbh | Thioether derivatives as protein kinase inhibitors |
WO2014109858A1 (en) | 2013-01-14 | 2014-07-17 | Amgen Inc. | Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture |
EP3252049A1 (de) | 2013-01-18 | 2017-12-06 | Bristol-Myers Squibb Company | Phthalazinone und isochinolinone als rock-inhibitoren |
WO2014113942A1 (en) | 2013-01-23 | 2014-07-31 | Merck Sharp & Dohme Corp. | Btk inhibitors |
US20140357636A1 (en) | 2013-02-21 | 2014-12-04 | Wayne Rothbaum | Treatment of Skeletal-Related Disorders |
US9050345B2 (en) | 2013-03-11 | 2015-06-09 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
TW201522337A (zh) | 2013-03-12 | 2015-06-16 | Arqule Inc | 經取代之三環吡唑並-嘧啶化合物類 |
TWI649308B (zh) | 2013-07-24 | 2019-02-01 | 小野藥品工業股份有限公司 | 喹啉衍生物 |
CA2922058A1 (en) | 2013-10-18 | 2015-04-23 | Medivation Technologies, Inc. | Heterocyclic compounds and methods of use |
WO2015066371A1 (en) | 2013-10-31 | 2015-05-07 | Forum Pharmaceuticals, Inc. | SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS |
ES2685661T3 (es) | 2013-11-08 | 2018-10-10 | Ono Pharmaceutical Co., Ltd. | Derivado de pirrolopirimidina |
JP6162904B2 (ja) * | 2014-02-03 | 2017-07-12 | カディラ ヘルスケア リミティド | 新規複素環式化合物 |
WO2015123282A1 (en) | 2014-02-12 | 2015-08-20 | Fotsing Joseph R | Improved process for the synthesis of substituted 1-benzyl-3-(1-(isoxazol-4-ylmethyl)-1h-pyrazol-4-yl)imidazolidine-2,4-diones |
WO2016097918A1 (en) | 2014-12-18 | 2016-06-23 | Pfizer Inc. | Pyrimidine and triazine derivatives and their use as axl inhibitors |
WO2016183071A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Hetero-tricyclic compounds and their use for the treatment of cancer |
WO2017027717A1 (en) | 2015-08-12 | 2017-02-16 | Incyte Corporation | Bicyclic fused pyrimidine compounds as tam inhibitors |
WO2017035366A1 (en) | 2015-08-26 | 2017-03-02 | Incyte Corporation | Pyrrolopyrimidine derivatives as tam inhibitors |
WO2017062797A1 (en) | 2015-10-07 | 2017-04-13 | The University Of North Carolina At Chapel Hill | The methods for treatment of tumors |
CO2018003968A2 (es) | 2015-10-13 | 2018-09-20 | Nihon Nohyaku Co Ltd | Compuesto heterocíclico condensado con contenido de grupo oxima o su sal, insecticida agrícola y hortícola que comprende el compuesto y método para controlar plagas. |
JP6905662B2 (ja) | 2015-11-14 | 2021-07-21 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. | 置換キノリン化合物の結晶形およびその医薬組成物 |
JP6921818B2 (ja) | 2015-11-14 | 2021-08-18 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. | 置換キノリン化合物の結晶形およびその医薬組成物 |
SG11201808582RA (en) * | 2016-03-28 | 2018-10-30 | Incyte Corp | Pyrrolotriazine compounds as tam inhibitors |
AR109452A1 (es) | 2016-04-22 | 2018-12-12 | Incyte Corp | Formulación farmacéutica de un inhibidor de lsd1 y método de tratamiento |
WO2017223414A1 (en) | 2016-06-24 | 2017-12-28 | Incyte Corporation | HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS |
JOP20170153A1 (ar) | 2016-07-15 | 2019-01-30 | Lilly Co Eli | نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة |
SG11201900238UA (en) | 2016-07-15 | 2019-02-27 | Ionis Pharmaceuticals Inc | Compounds and methods for modulation of smn2 |
PT3687996T (pt) | 2017-09-27 | 2022-01-21 | Incyte Corp | Sais de derivados de pirrolotriazina úteis como inibidores de tam |
US11241438B2 (en) | 2018-06-29 | 2022-02-08 | Incyte Corporation | Formulations of an AXL/MER inhibitor |
KR20230017165A (ko) | 2020-03-06 | 2023-02-03 | 인사이트 코포레이션 | Axl/mer 및 pd-1/pd-l1 억제제를 포함하는 병행 요법 |
-
2017
- 2017-03-27 SG SG11201808582RA patent/SG11201808582RA/en unknown
- 2017-03-27 PE PE2018001871A patent/PE20190175A1/es unknown
- 2017-03-27 PT PT177156205T patent/PT3436461T/pt unknown
- 2017-03-27 CA CA3019145A patent/CA3019145A1/en active Pending
- 2017-03-27 CR CR20180516A patent/CR20180516A/es unknown
- 2017-03-27 MY MYPI2018001653A patent/MY202022A/en unknown
- 2017-03-27 LT LTEPPCT/US2017/024270T patent/LT3436461T/lt unknown
- 2017-03-27 KR KR1020227045664A patent/KR102558066B1/ko active IP Right Grant
- 2017-03-27 SG SG10202009423QA patent/SG10202009423QA/en unknown
- 2017-03-27 CN CN202111584475.6A patent/CN114456176B/zh active Active
- 2017-03-27 HU HUE17715620A patent/HUE064656T2/hu unknown
- 2017-03-27 IL IL293496A patent/IL293496B2/en unknown
- 2017-03-27 UA UAA201810566A patent/UA123785C2/uk unknown
- 2017-03-27 AU AU2017241524A patent/AU2017241524B2/en active Active
- 2017-03-27 EP EP17715620.5A patent/EP3436461B1/de active Active
- 2017-03-27 KR KR1020237024326A patent/KR20230111268A/ko not_active Application Discontinuation
- 2017-03-27 JP JP2018550711A patent/JP7034084B2/ja active Active
- 2017-03-27 CN CN202111577669.3A patent/CN114456175B/zh active Active
- 2017-03-27 DK DK17715620.5T patent/DK3436461T3/da active
- 2017-03-27 IL IL261957A patent/IL261957B/en unknown
- 2017-03-27 SI SI201731469T patent/SI3436461T1/sl unknown
- 2017-03-27 MX MX2018011792A patent/MX2018011792A/es unknown
- 2017-03-27 WO PCT/US2017/024270 patent/WO2017172596A1/en active Application Filing
- 2017-03-27 MD MDE20190153T patent/MD3436461T2/ro unknown
- 2017-03-27 HR HRP20231614TT patent/HRP20231614T1/hr unknown
- 2017-03-27 EP EP23202364.8A patent/EP4321513A3/de active Pending
- 2017-03-27 CN CN201780031476.3A patent/CN109348715B/zh active Active
- 2017-03-27 TW TW111100154A patent/TWI828027B/zh active
- 2017-03-27 FI FIEP17715620.5T patent/FI3436461T3/fi active
- 2017-03-27 RS RS20231179A patent/RS65129B1/sr unknown
- 2017-03-27 KR KR1020187031294A patent/KR102483020B1/ko active IP Right Grant
- 2017-03-27 PL PL17715620.5T patent/PL3436461T3/pl unknown
- 2017-03-27 TW TW106110194A patent/TWI753892B/zh active
- 2017-03-27 US US15/469,975 patent/US9981975B2/en active Active
- 2017-03-27 ES ES17715620T patent/ES2967866T3/es active Active
-
2018
- 2018-05-04 US US15/971,017 patent/US10442810B2/en active Active
- 2018-09-27 CL CL2018002759A patent/CL2018002759A1/es unknown
- 2018-09-28 PH PH12018502102A patent/PH12018502102A1/en unknown
- 2018-10-26 EC ECSENADI201881153A patent/ECSP18081153A/es unknown
- 2018-10-26 CO CONC2018/0011550A patent/CO2018011550A2/es unknown
-
2019
- 2019-09-04 US US16/559,841 patent/US10844069B2/en active Active
-
2020
- 2020-10-19 US US17/073,987 patent/US11591338B2/en active Active
-
2021
- 2021-02-04 EC ECSENADI20218112A patent/ECSP21008112A/es unknown
- 2021-10-08 AU AU2021245220A patent/AU2021245220B2/en active Active
-
2022
- 2022-03-01 JP JP2022031060A patent/JP7271750B2/ja active Active
-
2023
- 2023-01-09 US US18/151,688 patent/US20240124463A1/en active Pending
- 2023-04-26 JP JP2023072156A patent/JP7500819B2/ja active Active
-
2024
- 2024-02-22 AU AU2024201172A patent/AU2024201172A1/en active Pending
- 2024-04-04 EC ECSENADI202426455A patent/ECSP24026455A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20231614T1 (hr) | Spojevi pirolotriazina kao tam inhibitori | |
HRP20240293T1 (hr) | Derivati kinazolina kao protutumorska sredstva | |
HRP20191027T1 (hr) | Derivati imidazopiridina kao inhibitori tiposinskih receptora kinaza | |
RU2019115115A (ru) | Производные пиперидина в качестве ингибиторов убиквитин-специфической протеазы 7 | |
RU2473549C2 (ru) | Пиримидиновые соединения, композиции и способы применения | |
JP2010510319A5 (de) | ||
HRP20171913T1 (hr) | Aminopirimidinilni spojevi kao inhibitori jak | |
HRP20191261T1 (hr) | Novi derivati pirazolo pirimidina i njihova uporaba kao inhibitora malt1 | |
HRP20210791T2 (hr) | 1-cijano-pirolidin spojevi kao usp30 inhibitori | |
HRP20180080T1 (hr) | Pirimidopirimidinoni korisni kao inhibitori wee-1 kinaze | |
HRP20192151T1 (hr) | Derivati izokromena kao inhibitori fosfoinozitid 3-kinaza | |
JP2018044008A5 (de) | ||
JP2018500376A5 (de) | ||
JP2016523911A5 (de) | ||
JP2018522859A5 (de) | ||
JP2016528298A5 (de) | ||
JP2016525092A5 (de) | ||
SI3087070T1 (en) | Pyrazolo (1,5-a) pyridine derivatives and processes for their use | |
RU2015148189A (ru) | ПРОИЗВОДНЫЕ 2-АМИДОПИРИДО[4, 3-d]ПИРИМИДИН-5-ОНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ WEE-1 | |
FI3773593T3 (fi) | Hidradenitis suppurativan hoito jak-estäjiä käyttäen | |
US11529350B2 (en) | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof | |
EP4237086A1 (de) | Heterocyclische spiroverbindungen und verfahren zur verwendung | |
RU2014109748A (ru) | Морфолино-замещенные производные бициклических пиримидинмочевины или карбамата в качестве ингибиторов mtor | |
JP2014528436A5 (de) | ||
JP2018535958A5 (de) |